The prevalence and incidence of medicinal cannabis on prescription in The Netherlands
- 2k Downloads
A growing number of countries are providing pharmaceutical grade cannabis to chronically ill patients. However, little published data is known about the extent of medicinal cannabis use and the characteristics of patients using cannabis on doctor’s prescription. This study describes a retrospective database study of The Netherlands.
Complete dispensing histories were obtained of all patients with at least one medicinal cannabis prescription gathered at pharmacies in The Netherlands in the period 2003–2010. Data revealed prevalence and incidence of use of prescription cannabis as well as characteristics of patients using different cannabis varieties.
Five thousand five hundred forty patients were identified. After an initial incidence of about 6/100,000 inhabitants/year in 2003 and 2004, the incidence remained stable at 3/100,000/year in 2005–2010. The prevalence rate ranged from 5 to 8 per 100,000 inhabitants. Virtually all patients used some form of prescription medication in the 6 months preceding start of cannabis use, most particularly psycholeptics (45.5 %), analgesics (44.3 %), anti-ulcer agents (35.9 %) and NSAIDs (30.7 %). We found no significant association between use of medication of common indications for cannabis (pain, HIV/AIDS, cancer, nausea, glaucoma) and variety of cannabis used.
This is the first nationwide study into the extent of prescription of medicinal cannabis. Although the cannabis varieties studied are believed to possess different therapeutic effects based on their different content of tetrahydrocannabinol (THC) and cannabidiol (CBD), no differences in choice of variety was found associated with indication.
KeywordsCannabis Therapeutic use Prevalence Incidence The Netherlands
AH is Head of R&D at Bedrocan BV, The Netherlands. The Dutch Association for Legal Cannabis and its Constituents as Medicine (NCSM foundation, Oegstgeest, The Netherlands) is gratefully acknowledged for providing the funds to collect data from the SFK database and providing the data to the authors. No additional funding was received for conducting this study.
- 1.Office of Medicinal Cannabis (OMC), Department of Health, official website http://www.cannabisbureau.nl (accessed Sep 2012)
- 2.Health Canada: Canadian department of Health, Marijuana Medical Access Program:http://hc-sc.gc.ca/dhp-mps/marihuana/index-eng.php (accessed Sep 2012)
- 3.Americans for Safe Access (ASA). Connecticut Becomes 17th Medical Marijuana State in the Face of Ongoing Federal Intimidation. Press release of 01 June 2012. http://www.safeaccessnow.org/article.php?id=7174 (accessed Sep 2012)
- 4.Hazekamp A, Mueller-Vahl K, Ware M et al The medicinal use of cannabis and cannabinoids; an international cross-sectional survey on methods of intake. J Psychoactive Drugs. in pressGoogle Scholar
- 5.Reiman AE (2007) Medical cannabis patients: patient profiles and health care utilization patterns. Complement Heal Pract Rev 12(1):31–50Google Scholar
- 12.NCSM: Dutch foundation for legal cannabis and its constituents as medicine. Survey among major health insurance companies [report in Dutch]. 2012 http://www.ncsm.nl/cfsystem/userData/pdf/1342695429__document__ncsm-vergoeding-medicinale-cannabis-2012.pdf (accessed Sep 2012)
- 14.WHO: World Health Organization Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/ (accessed Sep 2012)
- 15.Bedrocan BV Supplier of medicinal cannabis, official website: http://www.bedrocan.nl (accessed Sep 2012)
- 16.Hazekamp A (2006) An evaluation of medicinal grade cannabis in The Netherlands. Cannabinoids 1(1):1–9Google Scholar
- 21.International Association for Cannabinoid Medicine (IACM). Increasing numbers of patients use cannabis for medicinal purposes. Electronic newsletter of 08 April 2012. http://blog.norml.org/2012/04/11/estimate-worldwide-population-of-lawful-medical-marijuana-patients/ (accessed Sep 2012)
- 22.Van der Pol P, Liebregts N, De graaf R et al (2013) Validation of self-reported cannabis dose and potency: an ecological study. Addiction, submittedGoogle Scholar
- 26.Zajicek JP, Hobart JC, Slade A et al (2012) Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. Published online first: 12 July 2012. doi: 10.1136/jnnp-2012-302468